Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTATA-MSU: Canagliflozin vs Sitagliptin in T2DM on Metformin and Sulphonylurea
NCT01137812Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Hemoglobin A1c From Baseline at 52 weeks. Started Jul 2010; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01137812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137812.